{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T21:16:54Z","timestamp":1721769414160},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,1]]},"DOI":"10.1093\/cid\/cix036","type":"journal-article","created":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T13:27:11Z","timestamp":1485782831000},"page":"967-970","source":"Crossref","is-referenced-by-count":9,"title":["Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus\u2013Infected Patients With CD4 T-Cell Counts <100 Cells\/\u00b5L and Receiving Antiretroviral Therapy"],"prefix":"10.1093","volume":"64","author":[{"given":"Somnuek","family":"Sungkanuparph","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chutchaiwat","family":"Savetamornkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warisara","family":"Pattanapongpaiboon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"key":"key\n\t\t\t\t20170316074627_CIT0001","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170316074627_CIT0002","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/QAI.0b013e3182a39979","article-title":"Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries","volume":"65","author":"IeDEA and ART Cohort Collaborations","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170316074627_CIT0003","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170316074627_CIT0004","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1468-1293.2004.00201.x","article-title":"A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency","volume":"5","year":"2004","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20170316074627_CIT0005","author":"World Health Organization","year":"2008"},{"key":"key\n\t\t\t\t20170316074627_CIT0006","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11904-010-0052-6","article-title":"Management of cryptococcal meningitis in sub-saharan Africa","volume":"7","year":"2010","journal-title":"Curr HIV\/AIDS Rep"},{"key":"key\n\t\t\t\t20170316074627_CIT0007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2334-7-14","article-title":"Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole","volume":"7","year":"2007","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20170316074627_CIT0008","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1128\/AAC.01299-15","article-title":"Increased antifungal drug resistance in clinical isolates of cryptococcus neoformans in Uganda","volume":"59","author":"ASTRO-CM\/COAT Team","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170316074627_CIT0009","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2174\/157016207780636551","article-title":"Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection","volume":"5","year":"2007","journal-title":"Curr HIV Res"},{"key":"key\n\t\t\t\t20170316074627_CIT0010","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","article-title":"Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis","volume":"370","author":"COAT Trial Team","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170316074627_CIT0011","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/QAD.0b013e328352d1d8","article-title":"Decreasing incidence of cryptococcal meningitis in West Africa in the era of highly active antiretroviral therapy","volume":"26","year":"2012","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170316074627_CIT0012","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1473-3099(11)70245-6","article-title":"Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial","volume":"11","author":"Cryptococcal Trial Team","year":"2011","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/64\/7\/967\/11014334\/cix036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,23]],"date-time":"2022-07-23T01:09:19Z","timestamp":1658538559000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/2957272\/Primary"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,25]]},"references-count":12,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,1,25]]},"published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix036","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,25]]}}}